Zevra Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 4 days.
- Its last 9 Sell calls were followed by roughly flat moves (+1%) three months out.
- Recent price momentum is -14.8% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 11.0% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation B
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 7.2x | Better than 92% |
| Forward P/E | 10.6x | Better than 76% |
| Price / Sales | 3.7x | Better than 33% |
| P/E vs own 5-yr range | 82nd pctl | Better than 24% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability A
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 84.5% | Better than 93% |
| Operating margin | -4.0% | Better than 18% |
| Net margin | 78.2% | Better than 99% |
| Return on equity | 85.7% | Better than 97% |
| Return on invested capital | 53.0% | Better than 99% |
Momentum C
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -26.2% | Better than 22% |
| 6-month return | -12.7% | Better than 36% |
| 12-month return (ex latest month) | 14.1% | Better than 52% |
| Distance below 52-week high | 41.7% | Better than 26% |
Financial Health A
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 5.7x | Better than 88% |
| Debt to assets | 22.2% | Better than 53% |
| Interest coverage | 11.9x | Better than 75% |
Analyst View A+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 191.1% | Better than 94% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 9.07
- Open
- 8.89
- Day range
- 8.70 - 9.20
- Avg price
- 8.82
- Volume
- 1.15M
- Turnover
- 10.17M
- Turnover ratei
- 2.14%
- Volume ratioi
- 0.84
- Amplitudei
- 5.51%
- 52-week rangei
- 8.01 - 15.04
Valuation
- P/Ei
- 6.49
- P/E (TTM)i
- 7.18
- P/Bi
- 2.18
- EPSi
- 1.35
- Book value / shi
- 4.02
- Net profit
- 80.33M
- Net assets
- 238.91M
Share structure
- Market cap
- 521.26M
- Float capi
- 472.88M
- Shares out
- 59.50M
- Float sharesi
- 53.98M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- --
41.7% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-680.08K net over the window
Short interest
- Shares short
- 6.56M
- % of floati
- 11.04%
- Days to coveri
- 9.50
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Zevra Therapeutics (ZVRA)?
Zevra Therapeutics last traded at 8.76. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Zevra Therapeutics's market cap?
About 521.26M.
What is the P/E ratio of Zevra Therapeutics?
The trailing twelve-month P/E is 7.18. The Valuation tab shows it against the stock's own five-year range.
Does Zevra Therapeutics pay a dividend?
Zevra Therapeutics does not currently pay a regular dividend.
Is Zevra Therapeutics a buy according to analysts?
The consensus of 7 analysts is a Buy rating, with an average 12-month price target of 25.50, which implies 191.1% upside from the current price. This is not investment advice.
What is Zevra Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Zevra Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 20:02:31 · For reference only, not investment advice and not tailored to your situation.
Zevra Therapeutics discussion 0 comments